China Pharma Holding (STU:XQJ) Notes Receivable: €0.00 Mil (As of Mar. 2026)


STU:XQJ China Pharma Holding Inc STU:XQJ
26 GF Score
Price €26.80
GF Value €10.05
! 3 Warning Signs
View Full Analysis

What is China Pharma Holding Notes Receivable?

China Pharma Holding STU:XQJ 26 Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus rates STU:XQJ with a GF Score™ of 26/100 and a GF Value™ of €10.05. The stock has 3 warning signs investors should review.

China Pharma Holding's Notes Receivable for the quarter that ended in Mar. 2026 was €0.00 Mil.

China Pharma Holding's quarterly Notes Receivable declined from Sep. 2025 (€0.02 Mil) to Dec. 2025 (€0.00 Mil) but then stayed the same from Dec. 2025 (€0.00 Mil) to Mar. 2026 (€0.00 Mil).

China Pharma Holding's annual Notes Receivable declined from Dec. 2023 (€0.06 Mil) to Dec. 2024 (€0.02 Mil) and declined from Dec. 2024 (€0.02 Mil) to Dec. 2025 (€0.00 Mil).

China Pharma Holding Notes Receivable Related Terms

China Pharma Holding Notes Receivable Historical Data

* Premium members only.

The historical data trend for China Pharma Holding's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

China Pharma Holding Notes Receivable Chart

China Pharma Holding Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.08 0.01 0.06 0.02 0.00

China Pharma Holding Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.02 0.00 0.00
STU:XQJ
26GF Score
China Pharma Holding Inc STU:XQJ
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

China Pharma Holding Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of €0.00 Mil mean?
China Pharma Holding (STU:XQJ) has a Notes Receivable of €0.00 Mil as of Mar. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on China Pharma Holding and its competitors.
Is China Pharma Holding's Notes Receivable too high?
China Pharma Holding's current Notes Receivable is €0.00 Mil. Overall, China Pharma Holding has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does China Pharma Holding's Notes Receivable compare to TXMD and RMTI?
China Pharma Holding's Notes Receivable of €0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Drug Manufacturers company?
A good Notes Receivable depends on the Drug Manufacturers industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on China Pharma Holding and its competitors. China Pharma Holding's current Notes Receivable is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Pharma Holding stock overvalued right now?
China Pharma Holding (STU:XQJ) has a current Notes Receivable of €0.00 Mil. The stock's GF Value™ is €10.05, compared to a current price of €26.80 — trading 166.7% above its estimated fair value. The current Notes Receivable is €0.00 Mil. China Pharma Holding's overall GF Score™ is 26/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For China Pharma Holding (STU:XQJ), the current Notes Receivable is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is China Pharma Holding (STU:XQJ) Overvalued in 2026?

Based on GuruFocus' analysis, China Pharma Holding stock appears to be overvalued. The current stock price of €26.80 is trading 166.7% above its estimated GF Value™ of €10.05.

Key valuation signals for STU:XQJ:

  • Notes Receivable: €0.00 Mil
  • GF Value™: €10.05 vs. price of €26.80 (166.7% above fair value)
  • GF Score™: 26/100 with 3 warning signs

No single metric tells the full story. See the STU:XQJ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

China Pharma Holding Business Description

Other Exchanges CPHI:USA
Address No. 17, Jinpan Road, Second Floor, Jiahai Building, Hainan Province, Haikou, CHN, 570216
China Pharma Holding Inc is a drug manufacturing company. It is mainly engaged in the development, manufacture, and marketing of pharmaceutical products for human use in connection with a variety of high-incidence and high-mortality diseases and medical conditions prevalent in the People's Republic of China. The company mainly manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. The product line of the company includes cefaclor dispersible tablets, clarithromycin granules, roxithromycin dispersible tablets, andrographolide tablets, ozagrel sodium for injection, gastrodin injection, and others.
26GF Score

Get the complete analysis for STU:XQJ

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€26.80
Price
€10.05
GF Value